NCT05532319View on ClinicalTrials.gov

HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2023

Conditions
Liver Cancer
Interventions
COMBINATION_PRODUCT

HAIC sequential TAE combined with lenvatinib and tislelizumab

Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.

Trial Locations (1)

530021

Guangxi Medical University Cancer Hospital, Nanning

All Listed Sponsors
lead

Guangxi Medical University

OTHER